Choline C 11 injection

(Choline C 11 Injection®)

Choline c 11 injection

Drug updated on 9/5/2024

Dosage FormInjection (intravenous; 48 MBq to 1225 MBq [4 mCi to 33.1 mCi])
Drug ClassRadioactive diagnostic agents
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging. In these patients, 11 C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Choline C 11 Injection (choline c 11 injection) is indicated for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT), or magnetic resonance imaging. In these patients, 11 C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate-specific antigen (PSA) levels following initial therapy.
  • This summary is based on the review of five systematic review(s)/meta-analysis(es). [1-6]
  • PSMA-targeted imaging demonstrated superior diagnostic performance in primary and recurrent prostate cancer compared to [11C]choline and [18F]FACBC, though it is limited by heterogeneity in PSMA expression. 4. [11C]choline PET showed high sensitivity (71-84%) and specificity (86%) in detecting local and regional recurrences post-radical prostatectomy and achieved detection rates of up to 31.3% in early recurrent prostate cancer with PSA levels <0.5ng/ml.
  • In high-grade glioma, [11C]choline PET demonstrated 100% sensitivity and 70-88% specificity in differentiating tumor progression from treatment-related changes.
  • There is no safety information available in the reviewed studies.
  • There is no population types or subgroups information available in the reviewed studies.